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Objective: A reduced risk of some cancers and cardiovascular disease associated with 
phytoestrogen intake may be mediated through its effect on serum C-reactive protein (CRP) (an 
inflammation biomarker). Therefore, this study examined the associations between urinary 
phytoestrogens and serum CRP.  
Methods: Urinary phytoestrogen and serum CRP data, obtained from 6,009 participants, aged 
≥40 years, in the continuous National Health and Nutrition Examination Survey during 1999-
2010, were analyzed. 
Results: After adjustment for confounders, urinary concentrations of total and all individual 
phytoestrogens were inversely associated with serum concentrations of CRP (all p<0.004). The 
largest reductions in serum CRP (mg/L) per an interquartile range increase in urinary 
phytoestrogens (ng/mL) were observed for total phytoestrogens (β: -0.18; 95% CI: -0.22, -0.15), 
total lignan (β: -0.15; 95% CI: -0.18, -0.12), and enterolactone (β: -0.15; 95% CI: -0.19, -0.12). 
A decreased risk of having high CRP concentrations (≥ 3.0 mg/L) for quartile 4 vs. quartile 1 
was also found for total phytoestrogens (OR: 0.63; 95% CI: 0.53, 0.73), total lignan (OR: 0.64; 
95% CI: 0.54, 0.75), and enterolactone (OR: 0.59; 95% CI: 0.51, 0.69).   
Conclusion: Urinary total and individual phytoestrogens were significantly inversely associated 
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C-reactive protein (CRP) is an acute phase reactant and its plasma concentrations rise rapidly 
in a cytokine-mediated response to tissue injury, infection, or inflammation [1].  In previous 
studies, CRP levels have been positively associated with the risk of developing or dying from 
cancer [2,3] and cardiovascular disease [4,5].  Inflammation has been linked to carcinogenesis 
[6]. Experimental studies have shown that an increased risk of some cancers associated with 
certain inflammatory diseases was likely mediated through the inhibition of apoptosis [7], 
prolonged activation of signal transducers, activator of transcription 3 (STAT3) [8], and the 
deactivation of tumor necrosis factor alpha (TNF-α) [9].  As for the potential mechanisms by 
which CRP is involved in cardiovascular risk, in-vitro and animal studies have revealed that CRP 
may actively participate in plaque development through inducing monocyte adhesion to the 
endothelium [10] and promoting macrophage cholesterol accumulation [11]. Therefore, it is 
possible that reducing serum CRP levels may lower the risk of cancer and cardiovascular 
disease. 
Phytoestrogens are a group of botanical bioactive compounds that are structurally similar to 
estrogen [12]. The biological effects of phytoestrogens, observed in experimental studies, is in 
part ascribed to the competition of these compounds with endogenous estrogen for binding to 
estrogen receptors [13,14].  There are two principal classes of phytoestrogens, isoflavones 
(genistein and daidzein) and lignans (pinoresinol and lariciresinol). The richest dietary source of 
isoflavones is soy products, kudzu root, and American groundnuts [15,16], whereas dietary 
lignans are primarily obtained from flax seed, green tea, and strawberries [17].  Both isoflavones 
and lignans are metabolized by the gut bacteria to form their derivative compounds (equol and 
O-desmethylangolensin for isoflavones, and enterodiol and enterolactone for lignans) [18]. A 
growing number of studies have shown that urinary concentrations of phytoestrogens are 
reliable, objective biomarkers of their dietary intakes [19,20]. 
Intake of total and individual phytoestrogens and their biomarkers have been associated with 
a reduced risk of several cancers, cardiovascular disease, and other health conditions in some 
epidemiologic studies [21-24]. However, the biological mechanisms underlying these 
associations remain elusive. Epidemiologic studies evaluating the effect of dietary 
phytoestrogens on CRP levels have yielded inconsistent results, with both the CRP-lowering [25] 
and null [26] effects reported. It should be noted that most of those previous studies were 
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conducted among specific groups of subjects (e.g. postmenopausal women).  To date, little is 
known about the associations between dietary phytoestrogens and CRP levels in a large sample 
of the general population. Therefore, the present study was conducted to investigate this research 
question using data on urinary phytoestrogens and serum CRP, previously collected from the 
continuous National Health and Nutrition Examination Survey (NHANES) [27]. 
Subjects and Methods 
Study Population 
Data obtained from the NHANES for the years 1999-2010 were analyzed in this study. The 
data in this period of time were selected because 2010 is the most recent year for which data on 
urinary phytoestrogens were available at the time of the study. NHANES is an annual cross-
sectional study initiated in 1999 by the Center for Disease Prevention and Control (CDC) to 
assess the health and nutritional status of the general U.S. population.  Data collection and 
sampling procedures for NHANES have been described in detail elsewhere [28]. 
A total of 62,160 subjects enrolled in the NHANES in 1999-2010 completed the personal 
interview and health examination. The subjects included in the statistical analysis was confined 
to those who were 40 years of age or older primarily because the present study was intended to 
offer an insight on whether dietary intake of phytoestrogens alters the risk of cancer and 
cardiovascular diseases in part through their influence on inflammatory process. In addition, 
these two leading causes of death are not common among subjects who are younger than 40 
years old [29]. Urinary phytoestrogens and serum CRP were measured among a subset of all 
participants to reduce participant burden and facilitate the scheduling of the interview and 
completion of the health examination. All subjects in the subsample were randomly selected 
from the pool of total participants to obtain a nationally representative sample, with subsample 
weights calculated to account for probability of being selected into the subsample and additional 
non-response [27]. Excluding subjects who were less than 40 years old and those who did not 
have data on urinary phytoestrogens and serum CRP resulted in 6,009 subjects remaining for the 
data analysis.  
The approval of the present study by the Institutional Review Board of Indiana University 
was not applicable as the data analyzed are de-identified and available in public domains. 
Questionnaire Data Collection 
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NHANES participants were interviewed to collect data on demographic characteristics and 
lifestyle factors. Demographic variables relevant to this study included age, sex, race (non-
Hispanic White, non-Hispanic Black, and other race including multiracial), marital status 
(married or living with partner, widowed, divorced, or separated, and never married), and 
education level (less than high school, high school graduate or equivalent, and more than high 
school).  Lifestyle variables considered in this study were smoking status [never smokers 
(smoking 0 or <100 cigarettes in lifetime), former smokers (smoking ≥100 cigarettes in lifetime 
but not currently smoking), and current smoker], alcohol consumption (0, ≤1, and >1 
drink/week), and dietary intake of energy and nutrients. The dietary intake of the subjects was 
assessed by using a 24-hour dietary recall. Alcohol intake was determined with a comprehensive 
survey questionnaire. Body mass index (BMI) (kg/m2) was calculated from body height and 
weight measured during the health examination. 
Laboratory Measurements 
Urinary Phytoestrogens 
Urinary concentrations of isoflavones (daidzein, genistein, equol, and O-
desmethylangolensin) and lignans (enterodiol, and enterolactone) were measured using high 
performance liquid chromatography (HPLC) with tandem mass spectrometric (MS/MS) 
detection [30].  The methods for the collection and analysis of urine samples for phytoestrogen 
concentrations have been described in detail elsewhere [31].  Briefly, spot urine specimens were 
collected at the Mobile Examination Centers the morning after a recommended fast, processed, 
stored at -200C, and then shipped to the Division of Environmental Health Laboratory Sciences 
at the National Center for Health Statistics (NCHS) for analysis.  Urine samples were amended 
with stable isotope-labeled internal standards to improve method accuracy and precision, 
incubated with a deconjugation enzyme to allow the quantification of individual phytoestrogens, 
extracted using solid phase extraction to remove interferences and improve sensitivity, and then 
analyzed using negative ion mode electrospray ionization HPLC-MS/MS, an assay with a high 
degree of specificity for each of the analytes considered [31].  
Serum CRP 
 The methods for the collection and analysis of blood samples for serum CRP have been 
described in detail elsewhere [32].  Briefly, blood samples were obtained from the subjects via 
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venipuncture, processed, stored at ≤-20o C, and then shipped to the University of Washington in 
Seattle where serum CRP was quantified by latex-enhanced nephelometry [32].  
Statistical analysis  
Sample weights were applied to the data through the calculation of a 12-year weight variable 
according to the NCHS guidelines for combining two or more two-year cycles of the continuous 
NHANES data to produce unbiased national estimates. Urinary excretion of total phytoestrogens 
was calculated by summing the individual phytoestrogens for both total isoflavones and total 
lignans.  Demographic, anthropometric, and lifestyle characteristics of subjects as well as their 
urinary concentrations of total and individual phytoestrogen were compared by the quartiles of 
serum CRP. Chi-square tests and analysis of variance were employed to compare differences in 
categorical and continuous variables across CRP quartiles, respectively. As urinary 
phytoestrogens are continuous variables, their differences among subjects in different CRP 
quartiles were examined by analysis of variance.  
Urinary phytoestrogens and serum CRP were log-transformed to improve the normality of 
their distributions before data analysis. As expected, the log-transformation resulted in a 
substantial improvement in the normality of all those variables. Linear regression was performed 
to determine the associations between total and individual phytoestrogens and CRP. Partial 
regression coefficients were estimated for changes in serum CRP (mg/L) per an interquartile-
range (IQR) increase in urinary phytoestrogen (ng/mL).  The IQR was 1.63, 2.09, 2.31, 2.38, 
1.77, 3.36, 1.89, 1.94, and 2.19 ng/mL for total phytoestrogen, isoflavone, genistein, daidzein, 
equol, O-desmethylangolensin, total lignin, enterodiol, and enterolactone, respectively. Logistic 
regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for having 
serum CRP ≥ 3.0 mg/L in relation to urinary total and individual phytoestrogens. In the logistic 
regression, subjects were divided into quartiles, with those in the lowest quartile of total or each 
individual phytoestrogen serving as the reference group. The variables adjusted in the 
multivariable models of both the linear and logistic regressions were age, gender, race, 
education, BMI, smoking status, alcohol intake, and urinary creatinine. Urinary creatinine was 
included to control for variation in dilution effects derived from spot urine samples [20]. For 
both linear and logistic regressions, three models for the associations between urinary 
phytoestrogens and serum CRP were constructed: model 1 adjusted for creatinine level, model 2 
additionally adjusted for age, gender, and race, and model 3 additionally adjusted for education, 
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BMI, smoking status, and alcohol intake. The potential interactions of age, gender, BMI, 
education, smoking status, total energy intake, and sodium intake with urinary phytoestrogens in 
relation to serum CRP were tested and found to be not statistically significant. Marital status, and 
intake of alcohol, total energy, sodium, fat, and calcium were examined as potential confounders 
but not included in the final models because they were not statistically significant in the model or 
did not substantively alter risk estimates (<10%). A two-sided p-value of <0.05 was considered 
statistically significant. SPSS version 23 (Armonk, NY) was used for all statistical analyses. 
 Results 
Characteristics of study subjects by the quartiles of serum CRP levels are shown in Table 1.  
Subjects in the highest quartile were more likely to be older, female, non-Hispanic black, obese, 
less educated, current smokers, and non-drinkers than those in other three quartiles (p-values for 
differences in all these variables across the quartiles were <0.0001). Urinary concentrations of 
total and all individual phytoestrogens (except equol and enterodiol) monotonically decreased 
with increasing quartiles of serum CRP concentrations (all p <0.0001). The association of both 
equol and enterodiol with CRP concentration levels were not statistically significant. 
The results of multivariable linear regression analysis are presented in Table 2. After 
adjusting for confounders, urinary concentrations of total and all individual phytoestrogens were 
inversely associated with serum concentrations of CRP (all p<0.0001, except equol for which 
p=0.003). For the fully-adjusted model 3, the largest reduction in serum CRP (mg/L) associated 
with an interquartile range increase in urinary phytoestrogens (ng/mL) was observed for total 
phytoestrogens (β: -0.18; 95% CI: -0.22, -0.15), followed by total lignan (β: -0.15; 95% CI: -
0.18, -0.12) and enterolactone (β: -0.15; 95% CI: -0.19, -0.12). 
The results of multivariable logistic regression analysis were displayed in Table 3. Higher 
urinary concentrations of total and all individual phytoestrogens (except enterodiol) were 
associated with a reduced risk of having high serum concentrations of CRP (≥ 3.0 mg/L) 
independent of all confounders adjusted in model 3 (p-values for the trends for all 
phytoestrogens were ≤0.01). Similar to the results of the linear regression analysis, the strongest 
inverse associations were observed for total phytoestrogens (OR: 0.63; 95% CI: 0.53, 0.73), total 
lignan (OR: 0.64; 95% CI: 0.54, 0.75), and enterolactone (OR: 0.59; 95% CI: 0.51, 0.69). These 
ORs for having high concentrations of CRP were determined by comparing values for subjects in 
quartile 4 of each of those phytoestrogens to those in quartile 1 of the respective phytoestrogen. 
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A comparison of the risk estimates obtained from the three fitted models in both the linear and 
logistic regression analyses show that the strength of the inverse associations between urinary 
phytoestrogens and serum CRP was generally weaker in the fully-adjusted model 3 than in the 
models 1 and 2, suggesting the confounding effects of education, BMI, cigarette smoking, and/or 
alcohol intake. When the regression analysis was restricted to subjects aged 50 years or older, the 
results described above materially remain unchanged, with an exception that the association 
between urinary equol and serum CRP became weaker and no longer statistically significant in 
the multiple linear regression analysis.  
Discussion 
The present study revealed significant inverse associations of urinary concentrations of total 
and individual phytoestrogens with serum concentrations of CRP in a nationally representative 
sample of the U.S. population. Furthermore, subjects with higher urinary concentrations of total 
and individual phytoestrogens (except enterodiol) were less likely to have high serum 
concentrations of CRP (≥3.0 mg/L). These significant associations were independent of 
established or suspected confounders.  
Our observation that serum concentrations of CRP significantly decreased with increasing 
urinary concentrations of phytoestrogens is overall consistent with the results of some previous 
studies [25,33-36]. In a randomized, double-blind, placebo-controlled dietary intervention trial, 
117 postmenopausal women were asked to consume either isoflavone-enriched (50 mg/day) or 
placebo cereal bars for eight weeks, with a washout period of eight weeks between the crossover. 
The isoflavone supplementation resulted in a significant reduction of plasma CRP concentrations 
but did not alter the levels of other inflammatory biomarkers of cardiovascular disease risk. 
Specifically, OR (95% CI) for CRP >1 mg/L for isoflavone compared with placebo was 0.43 
(0.27, 0.69) [25].  In another dietary intervention study, 60 patients with subclinical 
hypothyroidism were randomly assigned to receive either low-dose (2 mg/day) or high-dose (16 
mg/day) phytoestrogen supplementation for eight weeks, and then crossed over after an eight-
week washout period. The high-dose phytoestrogen supplementation significantly reduced CRP 
levels in this patient population [33].   
However, the potential beneficial effect of phytoestrogen intake on CRP levels were not 
confirmed in some other randomized intervention trials [26,37]. For example, one study tested 
the effect of isoflavone supplementation with a dose of 114 mg/day among 56 postmenopausal 
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women with a history of breast cancer [26], and another study evaluated changes in CRP 
concentrations after one-month supplementation of high-dose isoflavones (73 mg/day) in 
comparison with the low-dose intervention (10 mg/day) among 41 postmenopausal women and 
hypercholesterolemic men [37]. To date, the majority of published studies on the associations 
between phytoestrogen intake and CRP levels have been intervention trials. These studies have 
advantages over observational studies largely because confounding can be eliminated or 
minimized if randomization procedure is successfully implemented at the time of group 
assignment. However, randomized intervention trials are subject to several weaknesses. Dietary 
intake of phytoestrogens from a normal Western diet is approximately 2 mg/day [33], but most 
previous randomized trials adopted a dose of isoflavones that are far beyond this amount. Other 
weaknesses of those studies include small sample size (n<150 for most trials), inadequate 
compliance of subjects to intervention measures, and dropouts of subjects during follow-up.   
 There are several possible mechanisms by which high intake of phytoestrogens might 
decrease CRP levels in human populations. It has been reported that phytoestrogens possess 
antioxidant properties [38,39]. Previous studies have shown that total antioxidant capacity or an 
increased intake of antioxidants was inversely associated with blood levels of CRP [40,41]. In 
addition, it has been found that orally delivered estrogen preparations resulted in an increased 
levels of CRP [42,43]. Therefore, competitive binding of phytoestrogens to estrogen receptors 
may counteract the promoting effects of endogenous or pharmacological estrogens on CRP 
levels. It is also possible that intake of phytoestrogens in Western populations is a surrogate of an 
overall healthy diet or another nutrient(s) that is truly associated with a reduction in CRP levels. 
This possibility is indirectly supported by the overall attenuation of our observed inverse 
association between urinary phytoestrogens and serum CRP after adjustment for socioeconomic 
and lifestyle factors (education, BMI, cigarette smoking, and alcohol consumption). However, 
caution should be exercised as the potential mechanisms discussed above need to be further 
clarified by additional studies. 
 There are several strengths in the present study. A major strength is that it is among the first 
to investigate the associations between urinary phytoestrogens and serum CRP in a large 
representative sample of the U.S. population. Most previous studies published to date on this 
topic have been randomized trials carried out among specific population sub-groups (e.g. 
postmenopausal women or hypercholesterolemic men), which limits the extrapolation of the 
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results obtained from those studies to the general population. Another major strength of the 
present study is that urinary concentrations of phytoestrogens measured as biomarkers of their 
dietary intake are free from recall bias that is frequently inherent in questionnaire-based dietary 
assessment. In addition, urinary phytoestrogen concentrations are capable of capturing dietary 
intake of total and individual phytoestrogens from both food sources and soy additives to 
processed foods as well as their metabolites produced by the gut bacteria (e.g. equol and O-
desmethylangolensin, which are not associated with dietary intake) [44]. Finally, measuring 
urinary lignans allows us to estimate their dietary intake. It is not possible to determine lignan 
intake using dietary assessment instruments as no reliable food composition database on this 
group of compounds are available at this time [19]. 
  The present study also has several weaknesses. As it is a cross-sectional study, it is not 
possible for us to make any causal inference on the observed inverse associations between 
urinary phytoestrogens and serum CRP. Urinary concentrations of phytoestrogens were 
determined for only one point in time and therefore might not reflect the usual dietary intake of 
study subjects if within-person variation is substantial. Nevertheless, a British study has shown a 
significant, strong correlations between phytoestrogen concentrations in spot urine and those in 
serum (r >0.80) [19]. Spot, rather than 24-hour, urine samples were collected from NHANES 
participants primarily for feasibility reasons. Measuring phytoestrogens in spot urine is a 
potential weakness as the concentrations of these compounds are affected by urine dilution. To 
control for variation in urine dilution, concentrations of total and each individual phytoestrogen 
were normalized to urinary creatinine. This is a commonly used method to address this 
methodological issue [20,45] because the excretion of creatinine by glomerular filtration 
physiologically occurs at a relatively constant rate [46]. Furthermore, only a modest correlation 
between dietary intake of total and individual phytoestrogens and their respective concentrations 
in urine (r = 0.29-0.54 for isoflavone; r=0.40 for lignan) were observed in most validation studies 
[19,47,48]. 
We are aware that two other studies have investigated the effect of urinary excretion of some 
phytoestrogens on serum levels of CRP among participants in the NHANES [35,36]. While 
Eichholzer et al. evaluated the association between urinary lignans and serum CRP [35], Nicastro 
et al. examined the association between urinary isoflavones and serum CRP [36]. Compared with 
those studies, the present study offers a more robust and comprehensive evidence that urinary 
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concentrations of total phytoestrogens, total isoflavones, total lignans, and individual 
phytoestrogens were inversely associated with serum CRP. First, the present study investigated 
the associations between urinary phytoestrogens and serum CRP among a larger number of 
participants in the NHANES over a longer period of time (6009 subjects in 1999-2010) than the 
Eichholzer et al. study (2628 subjects in 1999-2004 and 2028 subjects in 2005-2008) and the 
Nicastro et al. study (1683 subjects in 2005-2008). Therefore, our study has substantially 
expanded and strengthened the findings of those two previous studies. Second, the present study 
evaluated the associations between urinary phytoestrogens and serum CRP among NHANES 
participants of a more biologically relevant age range. Both previous studies analyzed the data 
collected from the participants aged 18 years or older. As mentioned previously, it is more 
methodologically appropriate to evaluate the associations between urinary phytoestrogens and 
serum CRP among subjects aged 40 years or older because such an analysis of mid-aged or old 
subjects could help to elucidate whether inflammation is involved in biological mechanisms 
linking dietary intake of phytoestrogens to the risk of cancer and cardiovascular diseases, major 
chronic conditions with low incidence rates among subjects aged 40 years or younger. 
In summary, the present study found that higher urinary concentrations of total and 
individual phytoestrogens were associated with reduced serum concentrations of CRP, with the 
largest reduction observed for total phytoestrogens, lignan, and enterolactone. A growing body 
of evidence indicates that inflammation is involved in the occurrence of cancer and 
cardiovascular disease [49], which is supported by an increased risk of these diseases associated 
with high CRP levels in epidemiological studies [50,51] . Previous studies have overall 
suggested that increased phytoestrogen consumption confers a beneficial effect on some cancers 
and cardiovascular disease through its influence on inflammation-mediated pathogenesis [52,53]. 
Therefore, the findings of the present study offer a novel biological basis for using 
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Table 1 Characteristics of subjects by quartiles of serum C-Reactive Protein (mg/L) in the continuous 
National Health and Nutrition Examination Survey, 1999-2010 
  Serum C-Reactive Protein (mg/L) 
 Quartile 1 Quartile 2 Quartile 3 Quartile 4  
Characteristics 0.1 - 0.8 0.9 - 2.1 2.2 - 4.9 5.0 - 296.0  
  n = 1,801 n = 1,847 n = 1,777 n = 1,763 p-value 
Age [Mean (SD)] 54.9 (11.9) 57.3 (12.2) 57.7 (12.2) 56.8 (12.0) <0.0001 
Gender (%)      
     Male 52.6 52.1 48.7 36.8 <0.0001 
     Female 47.4 47.9 51.3 63.2  
Race/Ethnicity (%)      
     Non-Hispanic White 77.8 76.8 75.2 73.5 <0.0001 
     Non-Hispanic Black 7.4 8.5 9.0 13.7  
     Other 14.8 14.7 15.8 12.8  
BMI1 [Mean (SD)] 25.5 (4.4) 27.9 (5.1) 29.7 (5.7) 32.4 (7.8) <0.0001 
Education (%)      
     Less than High School 15.5 17.8 22.2 23.6 <0.0001 
     High School Graduate or Equivalent 25.7 24.6 27.1 26.7  
     More than High School 58.8 57.6 50.7 49.8  
Smoking Status (%)      
     Never Smoker 51.2 50.9 48.5 46.1 <0.0001 
     Former Smoker 32.4 32.4 29.7 28.9  
     Current Smoker 16.4 16.8 21.8 25.0  
Alcohol Intake (%)      
     0 drinks/week 28.7 34.9 37.3 41.3 <0.0001 
     ≤ 1 drink per week 37.2 35.6 36.1 37.3  
     > 1 drink per week 34.1 29.6 26.6 21.4  
Urinary Phytoestrogens (ng/mL) [Mean (SD)] 
     Total Phytoestrogens 2266 (6223) 1613 (3010) 1550 (3666) 1243 (4159) <0.0001 
     Total Isoflavones 909 (3437) 640 (2153) 562 (2324) 488 (1602) <0.0001 
     Genistein 227 (966) 167 (720) 135 (615) 127 (407) <0.0001 
     Daidzein 482 (2029) 339 (1268) 296 (1336) 254 (824) <0.0001 
     Equol 80 (717) 51 (392) 54 (446) 49 (407) 0.24 
     O-desmethylangolensin 124 (695) 86 (408) 81 (510) 61 (463) 0.004 
     Total Lignans 1358 (4145) 973 (1912) 987 (2689) 756 (2166) <0.0001 
     Enterodiol 161 (603) 120 (336) 174 (1087) 188 (1800) 0.27 
     Enterolactone 1197 (3864) 854 (1730) 813 (1967) 568 (1057) <0.0001 







Table 2 Multiple regression analysis of serum C-reactive protein on urinary excretion of 
total and individual phytoestrogens among 6,009 subjects in the continuous National 
Health and Nutrition Examination Survey, 1999-2010 
  Serum C-Reactive Protein (mg/L) 
Urinary Phytoestrogen (ng/mL) Model 1 Model 2 Model 3 
Total Phytoestrogen    
     β (95% CI) -0.28 (-0.31, -0.24) -0.31 (-0.35, -0.28) -0.18 (-0.22, -0.15) 
     p-value <0.0001 <0.0001 <0.0001 
Total Isoflavone       
     β (95% CI) -0.14 (-0.18, -0.11) -0.16 (-0.20, -0.13) -0.11 (-0.14, -0.07) 
     p-value <0.0001 <0.0001 <0.0001 
Genistein       
     β (95% CI) -0.11 (-0.15, -0.07) -0.13 (-0.17, -0.09) -0.08 (-0.12, -0.05) 
     p-value <0.0001 <0.0001 <0.0001 
Daidzein       
     β (95% CI) -0.13 (-0.17, -0.09) -0.14 (-0.18, -0.10) -0.10 (-0.14, -0.07) 
     p-value <0.0001 <0.0001 <0.0001 
Equol       
     β (95% CI) -0.08 (-0.12, -0.04) -0.10 (-0.14, -0.06) -0.05 (-0.09, -0.02) 
     p-value <0.0001 <0.0001 0.003 
O-desmethylangolensin       
     β (95% CI) -0.17 (-0.22, -0.13) -0.20 (-0.24, -0.15) -0.14 (-0.18, -0.10) 
     p-value <0.0001 <0.0001 <0.0001 
Total Lignan       
     β (95% CI) -0.24 (-0.28, -0.20) -0.27 (-0.31, -0.24) -0.15 (-0.18, -0.12) 
     p-value <0.0001 <0.0001 <0.0001 
Enterodiol       
     β (95% CI) -0.13 (-0.16, -0.09) -0.15 (-0.18, -0.12) -0.07 (-0.10, -0.04) 
     p-value <0.0001 <0.0001 <0.0001 
Enterolactone       
     β (95% CI) -0.23 (-0.27, -0.20) -0.26 (-0.29, -0.22) -0.15 (-0.19, -0.12) 
     p-value <0.0001 <0.0001 <0.0001 
β is the partial regression coefficient that indicates changes in serum C-reactive protein (mg/L) per an 
interquartile range increase in urinary phytoestrogens (ng/mL). 
Model 1: adjustment for creatinine level; model 2: additional adjustment for age, gender, and race; and model 3: 













Table 3 ORs (95% CIs) for high concentrations of serum C-reactive protein (CRP) in relation to 
quartiles of urinary concentrations of total and individual phytoestrogens in the continuous National 
Health and Nutrition Examination Survey, 1999-2010 
  Quartile of Urinary Phytoestrogens (ng/mL)  
 Q1 Q2 Q3 Q4 p-trend 
Total Phytoestrogen       
Subjects with CRP ≥ and < 3 mg/L 780 / 1017 744 / 1055 633 / 1163 542 / 1254   
Concentrations (Median) 159 484 1019 2797  
Model 1 Reference 0.88 (0.77 - 1.00) 0.66 (0.57 - 0.75) 0.50 (0.43 - 0.58) <0.0001 
Model 2 Reference 0.83 (0.72 - 0.95) 0.60 (0.52 - 0.70) 0.45 (0.39 - 0.53) <0.0001 
Model 3 Reference 0.88 (0.76 - 1.02) 0.67 (0.58 - 0.78) 0.63 (0.53 - 0.73) <0.0001 
Total Isoflavone       
Subjects with CRP ≥ and < 3mg/L 718 / 1078 696 / 1104 671 / 1124 614 / 1183   
Concentrations (Median) 23 69 181 834  
Model 1 Reference 0.90 (0.78 - 1.03) 0.83 (0.73 - 0.96) 0.72 (0.62 - 0.83) <0.0001 
Model 2 Reference 0.89 (0.77 - 1.02) 0.81 (0.71 - 0.94) 0.69 (0.60 - 0.79) <0.0001 
Model 3 Reference 0.86 (0.74 - 1.00) 0.75 (0.65 - 0.88) 0.73 (0.63 - 0.86) 0.002 
Genistein       
Subjects with CRP ≥ and < 3mg/L 695 / 1106 701 / 1093 673 / 1124 629 / 1167   
Concentrations (Median) 4 15 43 214  
Model 1 Reference 0.98 (0.85 - 1.12) 0.90 (0.78 - 1.03) 0.80 (0.70 - 0.92) 0.001 
Model 2 Reference 0.96 (0.84 - 1.11) 0.89 (0.78 - 1.03) 0.78 (0.67 - 0.90) <0.0001 
Model 3 Reference 0.95 (0.82 - 1.11) 0.85 (0.73 - 0.99) 0.80 (0.69 - 0.94) 0.010 
Daidzein       
Subjects with CRP ≥ and < 3mg/L 707 / 1094 710 / 1084 641 / 1156 641 / 1156   
Concentrations (Median) 9 31 95 435  
Model 1 Reference 0.97 (0.85 - 1.11) 0.81 (0.71 - 0.93) 0.80 (0.70 - 0.92) 0.003 
Model 2 Reference 0.95 (0.83 - 1.09) 0.80 (0.70 - 0.92) 0.77 (0.67 - 0.89) 0.001 
Model 3 Reference 0.94 (0.81 - 1.09) 0.77 (0.66 - 0.90) 0.79 (0.67 - 0.92) 0.009 
Equol       
Subjects with CRP ≥ and < 3mg/L 682 / 1077 667 / 1087 664 / 1094 616 / 1138   
Concentrations (Median) 2 5 10 28  
Model 1 Reference 0.95 (0.83 - 1.09) 0.90 (0.78 - 1.03) 0.78 (0.67 - 0.90) <0.0001 
Model 2 Reference 0.94 (0.82 - 1.07) 0.90 (0.78 - 1.03) 0.77 (0.66 - 0.89) <0.0001 
Model 3 Reference 0.92 (0.80 - 1.07) 0.91 (0.78 - 1.06) 0.76 (0.65 - 0.89) 0.001 
O-desmethylangolensin       
Subjects with CRP ≥ and < 3mg/L 743 / 1064 697 / 1041 604 / 1154 599 / 1168   
Concentrations (Median) 0.3 2 8 71  
Model 1 Reference 0.93 (0.82 - 1.07) 0.73 (0.63 - 0.83) 0.71 (0.62 - 0.81) <0.0001 
Model 2 Reference 0.93 (0.81 - 1.07) 0.71 (0.62 - 0.82) 0.67 (0.58 - 0.77) <0.0001 
Model 3 Reference 0.91 (0.78 - 1.05) 0.71 (0.61 - 0.82) 0.72 (0.62 - 0.84) 0.002 
Total Lignan       
Subjects with CRP ≥ and < 3mg/L 789 / 1008 727 / 1073 639 / 1157 544 / 1251   
Concentrations (Median) 63 272 670 1836  
Model 1 Reference 0.85 (0.74 - 0.97) 0.68 (0.59 - 0.77) 0.50 (0.44 - 0.58) <0.0001 
Model 2 Reference 0.80 (0.70 - 0.92) 0.63 (0.55 - 0.72) 0.46 (0.40 - 0.53) <0.0001 
Model 3 Reference 0.87 (0.75 - 1.00) 0.73 (0.63 - 0.85) 0.64 (0.54 - 0.75) <0.0001 
Enterodiol       
Subjects with CRP ≥ and < 3mg/L 738 / 1058 649 / 1147 659 / 1137 649 / 1144   
Concentrations (Median) 6 27 64 202  
Model 1 Reference 0.79 (0.69 - 0.91) 0.78 (0.68 - 0.90) 0.75 (0.65 - 0.86) 0.004 
Model 2 Reference 0.77 (0.67 - 0.88) 0.76 (0.66 - 0.87) 0.69 (0.60 - 0.79) <0.0001 
Model 3 Reference 0.87 (0.75 - 1.01) 0.81 (0.70 - 0.95) 0.87 (0.75 - 1.02) 0.37 
Enterolactone       
Subjects with CRP ≥ and < 3mg/L 805 / 1004 720 / 1075 651 / 1141 522 / 1269   
Concentrations (Median) 30 200 573 1630  
Model 1 Reference 0.83 (0.73 - 0.95) 0.69 (0.61 - 0.79) 0.48 (0.41 - 0.55) <0.0001 
Model 2 Reference 0.80 (0.70 - 0.92) 0.66 (0.58 - 0.76) 0.45 (0.39 - 0.51) <0.0001 
Model 3 Reference 0.83 (0.72 - 0.96) 0.76 (0.65 - 0.88) 0.59 (0.51 - 0.69) <0.0001 
Model 1: adjustment for creatinine level; model 2: additional adjustment for age, gender, and race; and model 3: additional 
adjustment for education, BMI, smoking status, and alcohol intake. 
 
 
